Haitian Creole
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
5 rezilta yo
Symptom burden and life challenges reported by adult chordoma patients and their caregivers.
Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
This study aims to characterize the symptom burden and life challenges that chordoma patients and their caregivers experience.
In this cross-sectional study, we analyzed data from the Chordoma Foundation online community survey conducted in 2014. Frequency counts and percentages were calculated to
Phase II study of 9-nitro-camptothecin in patients with advanced chordoma or soft tissue sarcoma.
Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
OBJECTIVE
The purpose of this trial was to assess the objective clinical response, toxicity, and time to progression of treatment with 9-Nitro-Camptothecin (9-NC) in patients with advanced chordoma, soft tissue sarcoma (STS), and gastrointestinal stromal tumor (GIST).
METHODS
Patients with locally
[An application of posterior cervical and transoral approaches to treating primary malignant osseous tumors in craniovertebral junction]
Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
Objective: To investigate the surgical method for primary malignant osseous tumors in the craniovertebral junction (CVJ) and its effectiveness.
Methods: The clinical data of 7
Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors.
Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
Cross-talk between type I IGF receptor (IGF1R), insulin receptor (INSR), and epidermal growth factor receptor (EGFR) mediates resistance to individual receptor blockade. This study aimed to determine the MTD, safety, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of
Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study.
Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
BACKGROUND
Regorafenib has proven activity in patients with pretreated gastrointestinal stromal tumours and colorectal and hepatocellular carcinoma. We designed REGOBONE to assess the efficacy and safety of regorafenib for patients with progressive metastatic osteosarcoma and other bone sarcomas.
Baz done ki pi konplè remèd fèy medsin te apiye nan syans
- Travay nan 55 lang
- Geri èrbal te apiye nan syans
- Remèd fèy rekonesans pa imaj
- Kat entèaktif GPS - tag zèb sou kote (vini byento)
- Li piblikasyon syantifik ki gen rapò ak rechèch ou an
- Search remèd fèy medsin pa efè yo
- Izeganize enterè ou yo ak rete kanpe fè dat ak rechèch la nouvèl, esè klinik ak rive
Tape yon sentòm oswa yon maladi epi li sou remèd fèy ki ta ka ede, tape yon zèb ak wè maladi ak sentòm li itilize kont.
* Tout enfòmasyon baze sou rechèch syantifik pibliye
